-
Mashup Score: 1Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: - 1 year(s) ago
Abstract Background N-terminal pro–B-type natriuretic peptide (NT-proBNP) is used for diagnostic and prognostic evaluation in heart failure (HF). Previous clinical trials in heart failure with mild…
Source: JACC: Heart FailureCategories: Expert Picks, Latest HeadlinesTweet
-
Mashup Score: 2How to Initiate and Uptitrate GDMT in Heart Failure: Practical Stepwise Approach to Optimization of GDMT - 1 year(s) ago
IntroductionWith expanding evidence for benefit with guideline-directed medical therapy (GDMT) in patients with heart failure with reduced ejection fraction (HFrEF),1 heart failure with mildly reduced ejection fraction (HFmrEF), heart failure with preserved ejection fraction (HFpEF),2,3 and heart failure with improved ejection fraction (HFimpEF),1,3 clinicians commonly inquire on how to initiate,…
Source: JACC: Heart FailureCategories: Expert Picks, Latest HeadlinesTweet-
Initiation & uptitration of #GDMT in patients w/ #HF is the most important Tx to improve outcomes, morbidity & mortality. Dr. @BiykemB outlines evidence & implementation strategies for #HFrEF, #HFmrEF, & #HFpEF in this new #JACCHF editor's page: https://t.co/HitPwOBjF2 #ACCFIT https://t.co/zcD2wXCCxV
-
-
Mashup Score: 2Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Preserved Ejection Fraction - 1 year(s) ago
This prespecified analysis of the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) randomized clinical trial investigates if the effects of dapagliflozin on cardiovascular events vary with baseline kidney function.
Source: jamanetwork.comCategories: Cardiologists, Latest HeadlinesTweet-
#DELIVER 🔥 #Dapa efficacy in #HFmrEF & #HFpEF across the full spectrum of renal function 🧩 Another piece of the puzzlereinforcing the recent metanalysis on #SGLT2i on kidney function @mvaduganathan @BrighamResearch @gcfmd @KardiologieHH @DrMarthaGulati https://t.co/UvhNzEFbP1 https://t.co/hOoiIWQRWt
-
-
Mashup Score: 1
In patients with heart failure with mildly reduced or preserved ejection fraction, oral dapagliflozin improved heart failure outcomes to a similar extent in three glycaemia subgroups: normoglycaemia, prediabetes, and type 2 diabetes. Moreover, the heart failure benefits of dapagliflozin seem to be consistent across a continuous glycaemic range.
Categories: Cardiologists, Latest HeadlinesTweet-
*New* from #DELIVER in @TheLancetEndo Dapagliflozin in #HFmrEF & #HFpEF ✅ Consistent benefit across glycemic spectrum ✅ Efficacious irrespective of background metformin or insulin ✅ 0 cases of serious hypoglycemia or ketoacidosis in those w/o diabetes https://t.co/B6rq1UOW3d https://t.co/5PCjanlXBX
-
-
Mashup Score: 9Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Preserved Ejection Fraction - 2 year(s) ago
This prespecified analysis of the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) randomized clinical trial investigates if the effects of dapagliflozin on cardiovascular events vary with baseline kidney function.
Source: jamanetwork.comCategories: Cardiologists, Latest HeadlinesTweet-
#Dapagliflozin and Kidney Outcomes in Patients With #HeartFailure With Mildly Reduced or Preserved Ejection Fraction : A Prespecified Analysis of the #DELIVER Trial #HeartFailure #HFpEF #HFmrEF https://t.co/YP24gmTeMM @JavedButler1 @scottdsolomon @DrMarthaGulati @kidney_boy https://t.co/ZYcFXbbSNa https://t.co/ohhmVI51tx
-
-
Mashup Score: 1Implementing Sodium-Glucose Cotransporter-2 Inhibitor Therapy for Heart Failure: What Is the Message to DELIVER?∗ - 2 year(s) ago
Corresponding Author
Categories: Cardiologists, Latest HeadlinesTweet-
Long-term treatment with #dapagliflozin extends event-free survival by up to 2.0 to 2.5 years among middle aged and older individuals with #HFmrEF , #HFpEF or #HFimpEF https://t.co/2VLUJC5vsX @MichaelNassifMD @JJheart_doc @mvaduganathan @scottdsolomon @lamcardio #HeartFailure https://t.co/DPLsi79w8E
-
-
Mashup Score: 0Implementing Sodium-Glucose Cotransporter-2 Inhibitor Therapy for Heart Failure: What Is the Message to DELIVER?∗ - 2 year(s) ago
Corresponding Author
Categories: Cardiologists, Latest HeadlinesTweet-
Long-term treatment with #dapagliflozin extends event-free survival by up to 2.0 to 2.5 years among middle aged and older individuals with #HFmrEF , #HFpEF or #HFimpEF https://t.co/2VLUJC4XDp @MichaelNassifMD @JJheart_doc @mvaduganathan @scottdsolomon @lamcardio #HeartFailure https://t.co/DPLsi78Yj6 https://t.co/JEx1uFLaYL
-
-
Mashup Score: 3Cardiovascular magnetic resonance phenotyping of heart failure with mildly reduced ejection fraction - 2 year(s) ago
AbstractAims. The 2016 European Society of Cardiology Heart Failure Guidelines defined a new category: heart failure with mid-range ejection fraction (HFmrEF) o
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
#WhyCMR phenotyping of #HFmrEF This study provides a detailed description of the HFmrEF phenotype and future direction to confirm how the unique phenotype of #HFmrEF responds to Med therapy https://t.co/bEAEh9pOyL #EHJCVI @ESC_Journals @chiarabd @VDelgadoGarcia @iamritu https://t.co/C6zjcyJ88K
-
-
Mashup Score: 0Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction: - 2 year(s) ago
Abstract Background Atrial fibrillation (AF) is common in heart failure (HF), is associated with worse outcomes compared with sinus rhythm, and may modify the effects of therapy. Objectives This st…
Categories: Cardiologists, Latest HeadlinesTweet-
In patients with #HFpEF or #HFmrEF , the benefit of #dapagliflozin on symptoms and clinical events was not modified by baseline #Afib (Insight from the DELIVER) https://t.co/1lNOtaeHJy @mvaduganathan @scottdsolomon @HFpEF @lamcardio @gcfmd @SJGreene_md #HeartFailure @JACCJournals https://t.co/vixTIWcRND
-
-
Mashup Score: 2Time to Clinical Benefit of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction - 2 year(s) ago
This prespecified secondary analysis of the DELIVER trial evaluates the time course of benefits of dapagliflozin on clinically relevant outcomes in patients with HF with mildly reduced or preserved ejection fraction.
Source: jamanetwork.comCategories: Cardiologists, Latest HeadlinesTweet-
#DELIVER 💡 Early & sustained #SGLT2i benefit in #HFmrEF & #HFpEF Significant after just 2 weeks 🔥 🌟 Another reason to "start today" in #HF @JavedButler1 @mvaduganathan @MarcoMetra @hvanspall @DrMarthaGulati @GMCRosano @mmamas1973 @iamritu https://t.co/iS9zrfLkcs @JAMACardio https://t.co/JCESX6h4c7 https://t.co/RdmVEWQNdN
-
#Dapagliflozin is safe and improves outcomes irrespective of baseline NT-proBNP concentrations in #HFmrEF or #HFpEF, with the greatest absolute benefit likely seen in patients with higher NT-proBNP concentrations. https://t.co/7iYybpkvUL #JACCHF #DELIVER #SGLT2i #CardioTwitter https://t.co/MMqz5JLCNH